The preoperative SUVmax for 18F-FDG uptake predicts survival in patients with colorectal cancer

Shi, Debing; Cai, Guoxiang; Peng, Junjie; Li, Dawei; Li, Xinxiang; Xu, Ye; Cai, Sanjun

doi:10.1186/s12885-015-1991-5

Cited by 50 publications

(59 citation statements)

References 35 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Standard uptake values (SUV) and volume-based indices are most extensively investigated. In patients with colorectal cancer, these measures are demonstrated to be prognostic on pre-treatment [ 18 F]FDG PET in neoadjuvant [ 2 , 3 ] and metastatic settings [ 4 , 5 ]. However, the corrected tumour activity or metabolically active tumour volume (MATV) are only some of the PET characteristics which can be calculated from PET images.…”

Section: Introductionmentioning

confidence: 99%

Radiomics analysis of pre-treatment [18F]FDG PET/CT for patients with metastatic colorectal cancer undergoing palliative systemic treatment

Helden

Vacher

Wieringen

et al. 2018

Eur J Nucl Med Mol Imaging

View full text Add to dashboard Cite

BackgroundThe aim of this study was to assess radiomics features on pre-treatment [18F]FDG positron emission tomography (PET) as potential biomarkers for response and survival in patients with metastatic colorectal cancer (mCRC).MethodsPatients with mCRC underwent [18F]FDG PET/computed tomography (CT) prior to first- or third-line palliative systemic treatment. Tumour lesions were semiautomatically delineated and standard uptake value (SUV), metabolically active tumour volume (MATV), total lesion glycolysis (TLG), entropy, area under the curve of the cumulative SUV-volume histogram (AUC-CSH), compactness and sphericity were obtained.ResultsLesions of 47 patients receiving third-line systemic treatment had higher SUVmax, SUVpeak, SUVmean, MATV and TLG, and lower AUC-CSH, compactness and sphericity compared to 52 patients receiving first-line systemic treatment. Therefore, first- and third-line groups were evaluated separately. In the first-line group, anatomical changes on CT correlated negatively with TLG (ρ = 0.31) and MATV (ρ = 0.36), and positively with compactness (ρ = −0.27) and sphericity (ρ = −0.27). Patients without benefit had higher mean entropy (p = 0.021). Progression-free survival (PFS) and overall survival (OS) were worse with a decreased mean AUC [hazard ratio (HR) 0.86, HR 0.77] and increase in mean MATV (HR 1.15, HR 1.22), sum MATV (HR 1.14, HR 1.19), mean TLG (HR 1.16, HR 1.22) and sum TLG (HT1.12, HR1.18). In the third-line group, AUC-CSH correlated negatively with anatomical change (ρ = 0.21). PFS and OS were worse with an increased mean MATV (HR 1.27, HR 1.68), sum MATV (HR 1.35, HR 2.04), mean TLG (HR 1.29, HR 1.52) and sum TLG (HT 1.27, HR 1.80). SUVmax and SUVpeak negatively correlated with OS (HR 1.19, HR 1.21). Cluster analysis of the 10 radiomics features demonstrated no complementary value in identifying aggressively growing lesions or patients with impaired survival.ConclusionWe demonstrated an association between improved clinical outcome and pre-treatment low tumour volume and heterogeneity as well as high sphericity on [18F]FDG PET. Future PET imaging research should include radiomics features that incorporate tumour volume and heterogeneity when correlating PET data with clinical outcome.Electronic supplementary materialThe online version of this article (10.1007/s00259-018-4100-6) contains supplementary material, which is available to authorized users.

show abstract

Section: Introductionmentioning

confidence: 99%

Radiomics analysis of pre-treatment [18F]FDG PET/CT for patients with metastatic colorectal cancer undergoing palliative systemic treatment

Helden

Vacher

Wieringen

et al. 2018

Eur J Nucl Med Mol Imaging

View full text Add to dashboard Cite

show abstract

“…PET-CT is one of the currently available noninvasive imaging methods and is widely used in the diagnosis and staging of malignant tumors or monitoring of chemotherapeutic response in patients with cancer. 26 Our results revealed that SUV max was significantly higher in MET-positive expression tumors than in MET-negative expression tumors, suggesting that 18 F-FDG accumulation may reflect MET expression in lung adenocarcinomas.…”

Section: Discussionmentioning

confidence: 51%

<sup>18</sup>F-fluorodeoxyglucose uptake predicts MET expression in lung adenocarcinoma

An¹,

Zhou²,

Liu³

et al. 2017

OTT

View full text Add to dashboard Cite

ObjectiveMET is a member of the receptor tyrosine kinases. Several MET-targeting inhibitors and antagonistic antibodies have shown promising data in clinical trials of lung adenocarcinoma. Finding noninvasive diagnostic tools to estimate the status of MET is helpful in clinical practice. 18F-fluorodeoxyglucose positron emission tomography/computerized tomography (18F-FDG PET/CT) has been used routinely for the diagnosis and staging of tumors. However, the relationship between MET expression and 18F-FDG uptake has not been investigated yet. This study aimed to determine the correlation of MET expression with 18F-FDG uptake on PET-CT scan and whether or not 18F-FDG PET/CT can be used to predict the MET status of lung adenocarcinoma patients.Patients and methodsFifty-seven lung adenocarcinoma patients were analyzed in our study. Maximum standardized uptake value (SUVmax) was calculated in all PET/CT images. The expression levels of MET and two important glycolysis-related markers, glucose transporter 1 (GLUT1) and pyruvate kinase M2, were analyzed by immunohistochemistry of tissues. Spearman rank correlation was used to analyze the association between MET expression and SUVmax. In vitro MET knockdown in lung adenocarcinoma cells was used to examine the role of MET in tumor metabolism. The effect of MET on GLUT1 expression was investigated using Western blot assay and quantitative polymerase chain reaction.ResultsSUVmax was positively correlated with the expression levels of MET (r=0.458; P<0.001) and GLUT1 (r=0.551; P<0.001). SUVmax was significantly higher in patients with positive MET expression than in those with negative MET expression (9.92±6.62 vs 4.60±3.00; P=0.002). MET knockdown in lung adenocarcinoma cells led to a significant decrease in GLUT1 expression and 18F-FDG uptake.ConclusionMET could increase 18F-FDG uptake by upregulating GLUT1 expression. 18F-FDG PET/CT could be used to predict the MET status of lung adenocarcinoma patients and to supply valuable information to guide targeted therapy.

show abstract

“…However, if systemic metastasis is definitely confirmed via an abdominopelvic or chest CT, adding 18 F-fluorodeoxyglucose ( 18 F-FDG) positron-emission tomography (PET) or 18 F-FDG-PET/CT for further clinical decision is controversial. Some studies have demonstrated that conventional PET-derived parameters, such as maximum standardized uptake value (SUVmax), metabolic tumor volume (MTV), and total lesion glycolysis (TLG), carry their own significance in stratifying survival of patients with CRC [5][6][7][8]. However, other studies yielded equivocal results [9,10].…”

Section: Introductionmentioning

confidence: 99%

Radiomics Features of ¹⁸F-fluorodeoxyglucose Positron-Emission Tomography as a Novel Prognostic Signature in Colorectal Cancer

Kang

Lee

et al. 2019

Preprint

View full text Add to dashboard Cite

Word count: 3976 Number of tables: 5 Running Title: Radiomics of PET in colorectal cancer Abstract Purpose: The aim of this study was to investigate the prognostic value of radiomics signatures derived from 18 F-fluorodeoxyglucose ( 18 F-FDG) positron-emission tomography (PET) in patients with colorectal cancer (CRC). , we identified CRC patients who underwent 18 F-FDG-PET before starting any neoadjuvant treatments and surgery. Radiomics features were extracted from the primary lesions identified on 18 F-FDG-PET. Patients were divided into a training and a validation set by random sampling. A least absolute shrinkage and selection operator (LASSO) Cox regression model was applied for prognostic signature building with progression-free survival (PFS) using the training set. Using the calculated radiomics score, a nomogram was developed, and the clinical utility of this nomogram was assessed in the validation set. Results: Three-hundred-and-eight-one patients with surgically resected CRC patients (training set 228 vs. validation set 153) were included. In the training set, a radiomics signature called a rad_score was generated using two PET-derived features such as Gray Level Run Length Matrix_Long-Run Emphasis (GLRLM_LRE) and Grey-Level Zone Length Matrix_Short-Zone Low Gray-level Emphasis (GLZLM_SZLGE). Patients with a high-rad_score in the training and validation set had shorter PFS.Multivariable analysis revealed that the rad_score was an independent prognostic factor in both training and validation sets. A radiomics nomogram, developed using rad_score, nodal stage, and lymphovascular invasion, showed good performance in the calibration curve and comparable predictive power with the staging system in the validation set. Conclusion:Textural features derived from 18 F-FDG-PET images may enable more detailed stratification of prognosis in patients with CRC.

show abstract

The preoperative SUVmax for 18F-FDG uptake predicts survival in patients with colorectal cancer

Cited by 50 publications

References 35 publications

Radiomics analysis of pre-treatment [18F]FDG PET/CT for patients with metastatic colorectal cancer undergoing palliative systemic treatment

Radiomics analysis of pre-treatment [18F]FDG PET/CT for patients with metastatic colorectal cancer undergoing palliative systemic treatment

<sup>18</sup>F-fluorodeoxyglucose uptake predicts MET expression in lung adenocarcinoma

Radiomics Features of ¹⁸F-fluorodeoxyglucose Positron-Emission Tomography as a Novel Prognostic Signature in Colorectal Cancer

Contact Info

Product

Resources

About

The preoperative SUVmax for 18F-FDG uptake predicts survival in patients with colorectal cancer

Cited by 50 publications

References 35 publications

Radiomics analysis of pre-treatment [18F]FDG PET/CT for patients with metastatic colorectal cancer undergoing palliative systemic treatment

Radiomics analysis of pre-treatment [18F]FDG PET/CT for patients with metastatic colorectal cancer undergoing palliative systemic treatment

<sup>18</sup>F-fluorodeoxyglucose uptake predicts MET expression in lung adenocarcinoma

Radiomics Features of 18F-fluorodeoxyglucose Positron-Emission Tomography as a Novel Prognostic Signature in Colorectal Cancer

Contact Info

Product

Resources

About

Radiomics Features of ¹⁸F-fluorodeoxyglucose Positron-Emission Tomography as a Novel Prognostic Signature in Colorectal Cancer